abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Article

5 Apr 2007

Author:
Samantha Enslin, Business Report [So. Africa]

Aspen to market last-resort Aids drug across Africa

Aspen plans to market a salvage treatment, Prezista, for Aids patients in 20 sub-Saharan African countries through a deal with Ireland's Tibotec Pharmaceuticals [a division of Johnson & Johnson (J&J)]...The deal was structured so that Aspen would market Prezista...on a cost recovery basis...Tibotec…will not earn anything...Salvage treatment is a last resort for Aids patients…[Senior executive of Aspen] Nicolaou, said: "In Africa only about 20 percent to 25 percent of the 6 million Africans who require treatment are receiving it…"...